CA
NZ
UK
AU
IND
US
…
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, pediatrics and rare disease, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. It also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments. In addition, it develops a tool for primary care physicians and/or hospitals to assess cognitive decline. Its technology and associated services are used to quantify the effect of disease and drugs, devices, or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company serves biopharmaceutical companies, academic institutions, physicians, and patients. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cogstate Ltd develops and delivers computerized cognitive assessment tools and clinical-trial services used to measure brain function in neurology, oncology and psychiatry studies. Long-term growth may be driven by rising demand for validated digital cognitive endpoints in Alzheimer's and other CNS trials, an aging population, and broader adoption of remote and biomarker-enabled trial designs. Investors may find the company attractive because it appears positioned with regulatory-recognized tests, recurring service revenues from pharmaceutical clients, and scalable data assets supporting long-term contracts.
Primary investment risks include sensitivity to pharmaceutical R&D cycles and customer concentration, competition from other digital-assessment providers, and regulatory and data-privacy compliance demands that could increase costs or slow adoption.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | 16.47M | 13.91M | 10.65M | 3.03M | 10.69M |
| Net income | 12.16M | 10.14M | 5.45M | 3.57M | 7.52M |
| Selling general administrative | 12.90M | 12.82M | 13.61M | 14.41M | 11.80M |
| Selling and marketing expenses | - | 0.04M | 0.02M | 0.07M | 0.04M |
| Gross profit | 20.24M | 30.69M | 37.60M | 21.59M | 26.68M |
| Reconciled depreciation | 3.09M | 2.95M | 2.74M | 2.59M | 2.32M |
| Ebit | 12.35M | 13.98M | 7.16M | 3.09M | 10.78M |
| Ebitda | 15.51M | 16.93M | 9.90M | 5.69M | 13.11M |
| Depreciation and amortization | 3.16M | 2.95M | 2.74M | 2.59M | 2.32M |
| Operating income | 12.35M | 10.80M | 6.17M | 3.44M | 15.85M |
| Other operating expenses | 47.52M | 40.02M | 64.12M | 2.33M | 4.55M |
| Interest expense | 0.02M | 0.08M | 0.05M | 0.07M | 0.09M |
| Tax provision | 4.22M | 3.76M | 1.65M | -0.54M | 3.17M |
| Interest income | 0.88M | 0.93M | - | 0.70M | 0.05M |
| Net interest income | 0.86M | 0.85M | -0.05M | 0.63M | -0.04M |
| Income tax expense | 4.31M | 3.76M | 2.48M | -0.54M | 3.17M |
| Total revenue | 59.87M | 50.81M | 66.27M | 40.45M | 44.98M |
| Total operating expenses | 7.89M | 19.89M | 18.53M | 19.34M | 15.82M |
| Cost of revenue | 39.63M | 20.12M | 28.67M | 18.86M | 18.30M |
| Total other income expense net | 4.11M | 3.11M | 4.47M | 0.14M | -0.13M |
| Net income from continuing ops | 11.90M | 10.14M | 5.45M | 3.57M | 7.52M |
| Net income applicable to common shares | - | 10.14M | 5.45M | 3.57M | 7.52M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 78.03M | 64.77M | 86.60M | 54.07M | 58.45M |
| Intangible assets | 14.07M | 10.81M | 10.48M | 11.11M | 10.77M |
| Other current assets | 1.78M | 0.53M | 1.62M | 1.22M | 2.08M |
| Total liab | 19.78M | 16.88M | 25.33M | 16.38M | 25.52M |
| Total stockholder equity | 58.25M | 47.90M | 61.27M | 37.69M | 32.92M |
| Other current liab | 10.18M | - | 12.59M | 6.74M | 12.03M |
| Common stock | 39.78M | - | 54.76M | 36.32M | 36.15M |
| Capital stock | 39.79M | 37.76M | 36.57M | 36.32M | 36.15M |
| Retained earnings | 25.28M | 5.76M | 3.50M | -0.16M | -3.25M |
| Other liab | - | - | - | - | 6.67M |
| Other assets | - | - | - | 3.58M | 3.66M |
| Cash | 34.77M | 35.56M | 45.11M | 28.68M | 30.60M |
| Cash and equivalents | - | - | - | 20.19M | 18.19M |
| Total current liabilities | 16.67M | 13.34M | 18.84M | 12.17M | 18.26M |
| Current deferred revenue | 5.30M | - | 5.63M | 5.01M | 4.64M |
| Net debt | -34.41M | - | -44.10M | -28.41M | -29.37M |
| Short term debt | 0.12M | - | 0.33M | 0.24M | 0.64M |
| Short long term debt | - | - | 0.11M | 0.12M | 0.18M |
| Short long term debt total | 0.36M | - | 1.01M | 0.26M | 1.23M |
| Other stockholder equity | - | - | 0.00M | -54.28M | -47.64M |
| Property plant equipment | - | - | - | 0.60M | 2.02M |
| Total current assets | 58.99M | 50.30M | 65.08M | 38.78M | 42.00M |
| Net tangible assets | - | - | - | - | 22.16M |
| Net receivables | 22.44M | 12.81M | 18.35M | 7.63M | 8.32M |
| Inventory | - | - | 0.00M | 1.25M | 1.01M |
| Accounts payable | 1.08M | 1.52M | 0.30M | 0.19M | 0.95M |
| Accumulated other comprehensive income | -6.81M | - | 3.01M | 1.53M | 0.03M |
| Non currrent assets other | - | - | 15.69M | -17.58M | -18.52M |
| Non current assets total | 19.04M | 14.47M | 21.52M | 15.28M | 16.45M |
| Capital lease obligations | 0.36M | 0.47M | 0.56M | 0.26M | 1.23M |
| Long term debt total | - | - | - | 0.03M | 0.59M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -2.24M | -1.12M | -1.68M | -3.53M |
| Change to liabilities | - | - | - | 0.00M | -2.13M |
| Total cashflows from investing activities | -6.45M | -2.24M | -1.68M | -1.68M | -3.53M |
| Net borrowings | - | - | - | - | -0.65M |
| Total cash from financing activities | -4.04M | -3.79M | -4.91M | -0.89M | 0.76M |
| Change to operating activities | - | - | - | - | -0.64M |
| Net income | 12.16M | 10.14M | 8.32M | 5.36M | 10.89M |
| Change in cash | -2.81M | 5.44M | 2.11M | -1.92M | 6.96M |
| Begin period cash flow | 37.58M | 30.12M | 28.68M | 30.60M | 23.64M |
| End period cash flow | 34.77M | 35.56M | 30.12M | 28.68M | 30.60M |
| Total cash from operating activities | 9.69M | 11.48M | 8.67M | 0.98M | 14.09M |
| Issuance of capital stock | 1.44M | 1.15M | 0.62M | 0.18M | 1.41M |
| Depreciation | 3.16M | - | 4.18M | 1.30M | 1.78M |
| Other cashflows from investing activities | - | -1.95M | -1.00M | 0.53M | 0.03M |
| Dividends paid | 2.30M | - | - | - | 1.08M |
| Change to account receivables | -7.78M | -4.17M | -3.71M | 0.82M | -0.33M |
| Sale purchase of stock | -3.10M | -4.84M | -3.59M | -0.57M | -0.57M |
| Other cashflows from financing activities | -0.11M | -0.11M | -1.95M | -0.51M | -3.53M |
| Change to netincome | - | - | - | 1.06M | 2.32M |
| Capital expenditures | 0.53M | 3.07M | 2.88M | 2.21M | 3.56M |
| Change in working capital | -7.79M | -1.42M | -4.42M | 0.82M | -0.33M |
| Stock based compensation | - | - | 1.12M | 2.38M | 3.20M |
| Other non cash items | 2.17M | 12.90M | 13.10M | -5.67M | 1.41M |
| Free cash flow | 9.17M | 8.40M | 7.12M | -1.23M | 10.53M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CGS Cogstate Ltd |
-0.06 1.78% |
3.31 | 36.00 | 28.17 | 9.16 | 6.93 | 6.33 | 19.23 |
| PME Pro Medicus Ltd |
1.15 0.71% |
162.15 | 64.69 | 89.29 | 65.34 | 37.37 | 63.47 | 81.35 |
| AYA ARTRYA Ltd |
-0.24 6.30% |
3.57 | - | - | 23230.33 | 8.10 | 20004.93 | 0.33 |
| EIQ Echoiq Ltd |
-0.05 8.47% |
0.54 | - | - | 5395.50 | 40.77 | 5059.22 | -8.27 |
| ALC Alcidion Group Ltd |
- -% |
0.10 | - | 1.23 | 2.68 | 1.49 | 2.75 | 18.06 |
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, pediatrics and rare disease, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. It also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments. In addition, it develops a tool for primary care physicians and/or hospitals to assess cognitive decline. Its technology and associated services are used to quantify the effect of disease and drugs, devices, or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company serves biopharmaceutical companies, academic institutions, physicians, and patients. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Bradley John O'Connor B.Bus, C.A., CA | CEO, MD & Exec. Director | NA |
| Prof. Paul Maruff BBSc (Hons), Ph.D. | Founder & Chief Innovation Officer | NA |
| Mr. Darren Watson | Chief Financial Officer | NA |
| Mr. Benjamin Bloomfield | Chief Technology Officer | NA |
| Mr. Kenneth Billard | Chief Commercial Officer | NA |
| Dr. Chris Edgar Ph.D. | Chief Science Officer | NA |
| Ms. Rachel Colite | VP of Strategic Initiatives, Communication & People | NA |
| Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. | Company Sec. | 1970 |
| Dr. Amy E. Veroff Ph.D. | Principal Consultant | NA |
| Mr. Bradley John O'Connor B.Bus, C.A., CA | CEO, MD & Executive Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.18%
Communication Services
+0.02%
Consumer Cyclical
+0.43%
Consumer Defensive
+0.03%
Energy
-0.27%
Financial Services
+0.32%
Financials
-0.23%
Healthcare
-0.17%
Industrials
+0.45%
Real Estate
-0.02%
Technology
+0.20%
Utilities
+0.20%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...